Date: 2015-10-12
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the Crohn’s & Colitis Foundation of America Advances in Inflammatory Bowel Diseases (AIBD) on December 10-12, 2015, in Orlando, Florida
Company: DBV Technologies (France)
Product: Viaskin®
Action
mechanism: immunotherapy product. Viaskin® is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream.
Disease: Crohn's disease
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Country:
Trial details:
Latest
news: * On October 12, 2015, DBV Technologies announced that a communication on experimental results on the use of Epicutaneous Immunotherapy (EPIT®) in a model of Crohn’s disease will be presented at the Crohn’s & Colitis Foundation of America Advances in Inflammatory Bowel Diseases (AIBD) on December 10-12, 2015, in Orlando, Florida. A “First Evidence for the Treatment of Colitis by Epicutaneous Immunotherapy in a Murine Model” will be presented by Dr. David Dunkin, Assistant Professor in the Division of Pediatric Gastroenterology at The Icahn School of Medicine, at the Mount Sinai in New York, at an Oral Presentation on Saturday, December, 12, 2015 at 12.00 pm (local time). The abstract will be published in Inflammatory Bowel Diseases, February 2016 Issue. Crohn’s disease patients have a defect in inducing T-regulatory cells (Treg) via the gut. When Tregs are generated externally in response to food antigen and infused into patients, they suppress inflammation in Crohn’s via bystander suppression (Desreumaux et al., Gastroenterology, 2012). This study was conducted on C57Bl/6 mice exposed epicutaneously for 48 hours once a week for 3 weeks to Viaskin patches containing ovalbumin (Viaskin-OVA). This experiment assessed that Tregs could be induced by applying antigen to intact skin using an epicutaneous delivery device, Viaskin®, and that after their migration to the gut, Tregs could abrogate colitis via bystander suppression. Epicutaneous tolerance induction could have the potential to treat Crohn’s disease and further preclinical and clinical studies need to be conducted. DBV Technologies and The Icahn School of Medicine at Mount Sinai entered into a research collaboration agreement in February 2014 to investigate the efficacy of EPIT® using Viaskin® for the treatment of Crohn’s disease.
